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ABSTRACT
Background
The CRB-65 score is a clinical prediction rule that
grades the severity of community-acquired pneumonia
in terms of 30-day mortality.
Aim
The study sought to validate CRB-65 and assess its
clinical value in community and hospital settings.
Design of study
Systematic review and meta-analysis of validation
studies of CRB-65.
Method
Medline (1966 to June 2009), Embase (1988 to
November 2008), British Nursing Index (BNI) and
PsychINFO were searched, using a diagnostic
accuracy search filter combined with subject-specific
terms. The derived (index) rule was used as a
predictive model and applied to all validation studies.
Comparison was made between the observed and
predicted number of deaths stratified by risk group
(low, intermediate, and high) and setting of care
(community or hospital). Pooled results are presented
as risk ratios (RRs) in terms of over-prediction (RR>1)
or under-prediction (RR<1) of 30-day mortality.
Results
Fourteen validation studies totalling 397 875 patients
are included. CRB-65 performs well in hospitalised
patients, particularly in those classified as intermediate
(RR 0.91, 95% confidence interval [CI] = 0.71 to 1.17)
or high risk (RR 1.01, 95% CI = 0.87 to 1.16). In
community settings, CRB-65 over-predicts the
probability of 30-day mortality across all strata of
predicted risk, low (RR 9.41, 95% CI = 1.75 to 50.66),
intermediate (RR 4.84, 95% CI = 2.61 to 8.69), and
high (RR 1.58, 95% CI = 0.59 to 4.19).
Conclusion
CRB-65 performs well in stratifying severity of
pneumonia and resultant 30-day mortality in hospital
settings. In community settings, CRB-65 appears to
over-predict the probability of 30-day mortality across
all strata of predicted risk. Caution is needed when
applying CRB-65 to patients in general practice.
Keywords
general practice; meta-analysis; pneumonia; prognosis;
severity of illness index.
INTRODUCTION
Community-acquired pneumonia (CAP) has an annual
incidence of 5–11 per 1000, accounting for 5–12% of
all cases of adult lower respiratory tract infection
managed by GPs.1 Appropriate management for
patients with suspected CAP must be determined by
GPs at initial presentation, particularly with regard to
whether or not to manage a patient in the community
or refer them to hospital.2 The proportion of adults with
CAP who require hospital admission in the UK varies
between 22% and 42%.1 This proportion varies in
other countries, possibly due to differing structures of
primary and secondary healthcare systems.1
Furthermore, of those initially managed in the
community, less than 10% subsequently require
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hospital admission. At the other end of the severity
spectrum, between 5% and 10% of patients admitted
to hospital require management in an intensive care
unit (ICU).1
Severity assessment in patients with suspected CAP
plays a key part in planning appropriate management
in both community and hospital settings, as the setting
of care has an impact on the level of treatment given to
the patient as well as the overall costs of treatment.1
The CRB-65 score (Figure 1) is a clinical prediction rule
derived to determine the severity of CAP and to aid the
physician in arranging appropriate treatment.3 It ranks
patients into strata of low, intermediate, or high risk of
mortality based on four criteria (new-onset confusion;
respiratory rate ≥30/minutes; systolic blood pressure
<90 mmHg or diastolic blood pressure ≤60 mmHg;
and age ≥65 years), in terms of estimated mortality risk
(Figure 1). It is also forms the basis of an algorithm to
determine the most appropriate site of care.1 The CRB-
65 score is a simplified version of the CURB-65 rule
(inclusion of urea estimation: raised >7 mmol/l), and
has been advocated for use in community settings as
its criteria depend on clinical assessment (history and
physical examination) alone.4
There are specific methodological standards that are
applied to clinical prediction rules before their use in
clinical practice can be recommended. Ideally, a rule
undergoes three steps: derivation, narrow and broad
validation, and impact analysis (randomised controlled
trial assessing its effectiveness and cost-
effectiveness).5–7
The CRB-65 rule has been validated extensively in
separate studies, although for a clinical prediction rule
specifically intended for community use there have
been few validation studies performed wholly in
primary care.1,8 As clinical prediction rules may not
perform well in practice because of deficiencies in the
development methods or because of differences
between the original sample and the validation sample,
it is good practice to assess their validity across a
broad range of eligible patient groups.9 The aim of this
study was to perform a comprehensive systematic
review and meta-analysis of validation studies of CRB-
65, to determine its accuracy in predicting 30-day
mortality and assess how well it performs in
community and hospital settings.
METHOD
Search strategy
A search strategy was designed for PubMed in order to
retrieve all relevant articles. MeSH terms ‘community
acquired infection’, ‘respiratory tract infection’,
‘pneumonia’, ‘severity indices’, and ‘prognosis’ were
combined, and potential studies were retrieved. This
subject-specific search was combined with a
methodological filter for clinical prediction rules.10
PubMed was searched from 1966 to June 2009. In
addition, Embase, the Cochrane Library, and Medline
databases were searched for relevant studies. Google
Scholar was used to track references to each selected
study, and hand searches of references in the included
studies were also performed. Authors of published
studies were also contacted for additional data and for
knowledge of any unpublished studies.
Selection
Inclusion criteria for the systematic review were as
follows: (1) study design — cohort study; (2) patient
population — adult patients (≥16 years) with a primary
diagnosis of CAP; (3) explanatory variables — CRB-65
score calculated; (4) setting of care — community-
based or hospital-based patients; and (5) outcome
measure— death within 30 days. Studies that used the
same dataset for more than one publication were
included once in the meta-analysis.
Validity assessment
Quality assessment was independently performed by
two researchers following the methodological
standards of McGinn for validation studies of clinical
prediction rules.5
Data abstraction
Abstracts of potential studies were independently
How this fits in
The CRB-65 rule grades the severity of community-acquired pneumonia in
terms of 30-day mortality risk. Although it is intended for use in the community
setting the majority of validation studies are hospital based. This systematic
review suggests that the CRB-65 rule performs well in hospital settings but may
over-predict the probability of 30-day mortality in community settings, and
should be used with caution.
Systematic Review
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Any of:
• Confusiona
• Respiratory rate ≥30 minutes
• Blood pressure (SBP <90mmHg or DBP ≤60mmHg)
• Age ≥65 years
Score 1 point for each feature present
0 1 or 2 3 or 4
Consider hospital
referral
Urgent hospital
admission
Likely suitable for
home treatment
CRB-65 score
Figure 1. Severity
assessment by the
CRB-65 in terms of risk
strata and subsequent
management strategy for
patients with suspected
community-acquired
pneumonia.3,4
DBP = diastolic blood pressure; SBP = systolic blood pressure. aDefined as a Mental Test
Score of ≤8, or new disorientation in person, place or time. Predicted 30-day mortality:
CRB-65 score 0 = 1.2%. CRB-65 score 1 or 2 = 8.2%. CRB-65 score 3 or 4 – 31.3%.
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Outcome
Setting Study type Participants; age; sex Inclusion Exclusion measure
Barlow et al, Hospitalised Retrospective analysis n = 503; median 74 years Receiving antibiotics for One or more of: 30-day
200711 inpatients of prospectively (range 16–98 years); a suspected lower • non-pneumonia diagnosis mortality
collected data male n = 197 respiratory tract infection • aspiration, hypostatic or
(before and after study) + new infiltrate on chest hospital-acquired pneumonia
radiograph, or clinically • diagnosis of CAP changed
diagnosed as CAP by before discharge
specialist registrar or • HIV+, neutropenic or markedly
consultant doctor immunosuppressed
• progressive malignancy
• chronic respiratory disease
other than asthma or chronic
obstructive pulmonary disease
(COPD)
• age <16years
Bauer et al, CAPNETZ Consecutive prospective n = 2184: 1646 inpatients, New pulmonary infiltrate Acquisition pneumonia after 30-day
200612 centres, cohort 538 outpatients; mean 62.5 on chest radiograph + hospital admission; severe mortality
inpatients, years (range 18–99 years); one of: immunosuppression; expected
outpatients male n = 1245 • fever terminal event of severe chronic
• cough comorbidity; alternative diagnosis
• purulent sputum
• focal chest signs
• dyspnoea
• pleuritic pain
Bont et al, Primary care, Prospective consecutive n = 314; mean 77.3 years; One or more features of: One or more of: 30-day
20088 outpatients cohort male n = 145 • new localising signs • lung cancer mortality
present during chest • haematologic malignant
examination neoplasm
• new infiltrates on chest • HIV+
radiograph • immunosuppressive
• strong suspicion medication use
because of severe • hospitalised during 2 weeks
dyspnoea in a very ill prior to diagnosis
patient • nursing home residents
Buising et al, Emergency Prospective consecutive n = 722; median 73 years New respiratory symptom One or more of: Death +/–
200713 department cohort (range 18–98 years); + chest X-ray infiltrate • age <18 years requirement
male n = 411 • immunosuppression for
• chronic lung disease ventilatory
• nosocomial pneumonia support
• >24 hours in emergency
department
Capelastegui Emergency Retrospective application n = 1776; mean 61.8 years Pulmonary infiltrates on One or more of: 30-day
et al, 200614 department, of a prospective (standard deviation [SD] chest radiograph + • HIV mortality
substratified, consecutive cohort 20.5 years); male n = 1124 symptoms consistent • chronic immunosuppression
inpatients, with pneumonia: • hospitalised within previous
outpatients • cough 14 days
• dypsnoea
• fever
• pleuritic chest pain
Chalmers et al, Hospitalised Prospective observational n = 1007; mean 66 years New infiltrate on chest One or more of: 30-day
200815 inpatients cohort (range 50–78 years); male radiograph >3 or more of: • hospital-acquired pneumonia mortality
n = 500 • cough • active malignancy
• sputum production • immunosuppression
• breathlessness • pulmonary embolism
• pleuritic chest pain • palliative care patients
• haemoptysis
• fever
• headache
• signs on chest auscultation
Table 1. Characteristics of included studies.
Systematic Review
screened by two researchers and those considered
were read fully in duplicate and their suitability for
inclusion in the study was independently determined
by both researchers. Disagreements were managed
by consensus and the involvement of a third
researcher.
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Outcome
Setting Study type Participants; age; sex Inclusion Exclusion measure
Ewig et al, CAP Consecutive n = 388 406 Age ≥18 years; ICD-10- • Severe In-hospital
200922 performance retrospective cohort GM-codes for pneumonia immunosuppression mortality
programme, • Acute bronchitis
German BQS • Exacerbations of COPD
Kruger et al, CAPNETZ Consecutive prospective n = 1404: 545 outpatients, Age >18 years, new One or more of: 28-day
200816 centres, cohort 1001 inpatients; mean 61 pulmonary infiltrate on • systemic immune deficiency mortality
inpatients, years (range 18–98 year); chest radiograph + one of: • active TB
outpatients male n = 772 • fever • hospitalisation <4 weeks prior
• cough to infection
• purulent sputum
• focal chest signs
• dyspnoea
• pleuritic pain
Man et al, Hospitalised Consecutive prospective n = 1404; mean 72 years Acute infection pulmonary • Age <17 years 30-day
200717 inpatients cohort (range 17–103 years); male parenchyma + symptoms • Immunosuppression mortality
admitted n = 583 of acute infection + acute • Pulmonary TB
through infiltrate on chest • Hospitalised <14 days
emergency radiograph prior to presentation
department • Diagnosis other than CAP
after admission
Menendez Hospitalised Consecutive prospective n = 453; mean 67 years New radiographic infiltrate; • Admitted in the previous 30-day
et al, 200918 patients in cohort (SD 17.1 years); male at least two days of 15 days mortality
two tertiary n = 282 compatible symptoms • Immunosupressive
care centres or steroid treatment
• Leudopenia or neutropenia
• Do not resuscitate
Myint et al, Hospitalised Retrospective analysis of n = 192; median 77 years Clinical features of • Aspiration pneumonia 6-week
200623 inpatients two prospective (range 17–96 years); male pneumonia + new chest • Clinical diagnosis of CAP mortality
observational cohorts n = 111 radiograph shadow; without new chest X-ray shadow
2nd cohort age ≥65 years • TB
• Active malignancy
Schaaf et al, Hospitalised Consecutive prospective n = 105; mean 64.9 years Isolation of S. pneumoniae • Neoplasia 40-day
200719 inpatients cohort (range 24–96 years); male or positive urinary antigen • Immunosuppression mortality
n = 60 test + one or more of: • HIV+
• fever • Immunoglobulin deficiency
• respiratory symptoms
• auscultatory findings
• new infiltrate on chest
radiograph
Schuetz et al, Emergency Pooled data of two n = 372; median 73 years Presence of a new infiltrate Lower respiratory infections 30-day
200820 department randomised controlled (interquartile range on chest radiograph other than CAP: mortality
studies 59–82 years); male n = 244 + one of: • cough • cystic fibrosis
• sputum production • active pulmonary TB
• dyspnoea • hospital-acquired pneumonia
• fever >38.0°C • severe immunosuppression
• auscultatory findings
• leucocytotis or leucopenia
Zuberi Hospitalised Longitudinal cohort n = 137; mean 60.4 years Age ≥16 years + required • Pneumonia not primary cause 30-day
and Khan, inpatients (range 16–95 years); male admission for for admission mortality
200821 n = 74 management of CAP • Post-obstructive pneumonia
• TB
• Bronchiectasis
• Malignancy
• HIV
BQS = Bundesgeschäftsstelle Qualitätssicherung gGmbH. CAP = community-acquired pneumonia.
Table 1 continued. Characteristics of included studies.
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Statistical methods
The initial derivation study of the CRB-65 rule was
used as the predictive model to which all validation
studies were compared.3 The number of deaths as
predicted by the CRB-65 severity index was
compared to the observed number of deaths in each
of the validation studies, across the three strata of risk
in the CRB-65 rule — low risk (score = 0),
intermediate risk (score = 1 or 2), and high risk (score
= 3 or 4) (Figure 1). In order to calculate the predicted
score, the proportionate mortality estimate from the
original derivation study was applied according to the
three risk strata — low risk (mortality = 1.2%),
intermediate risk (mortality = 8.2%), and high risk
(mortality = 31.3%),3 an approach previously used in
a community-based validation study.8 The
predicted:observed risk ratios for these three risk
strata are presented separately for patients who were
treated in the community or in hospital. Results are
presented as risk ratios (RRs) with 95% confidence
intervals (CIs). RR<1 indicated an under-prediction of
death by the CRB-65 rule (the observed number of
deaths is greater than the predicted number) and
RR>1 indicated an over-prediction of death by the
CRB-65 rule (the observed number of deaths is less
than the predicted number). RR = 1 indicated a
perfect calibration between observed and predicted
deaths. Assessment of publication bias was also
made by means of generating a funnel plot, and
statistical testing for publication bias.
Review Manager 5 software from the Cochrane
Collaboration was used to perform the analysis,
determine heterogeneity, and produce forest plots.
RRs were calculated with 95% CIs using the
Mantel–Haenszel statistical method. A random-
effects analysis was performed, and heterogeneity
was described by the I2 statistic.
RESULTS
Description of included studies
The search identified 14 studies with a total of
397 875 patients (Figure 2).8,11–23 Table 1 summarises
the characteristics of the included studies. Additional
data were provided from three studies,13,15,23 and
clarification of included overlapping subjects
obtained from two other studies.12,16 Only one study
was performed entirely in a primary care setting,8
although two other studies did include data from
patients who were treated as outpatients.12,14 The
included studies ranged in size from 105 patients to
388 406 patients, with a broadly equal sex balance.
Two studies limited the inclusion for age to
≥65 years.8,23 Most studies also had mortality at
30 days as an outcome measure, corresponding
directly in timing to the original derivation study.3
However, two studies reported in-hospital mortality
and one reported mortality at 42 days.12,23 Thirty-day
mortality was obtained from the authors of one of
these studies,23 and in-hospital mortality was used as
an approximation to 30-day mortality in the other
two. The quality-assessment standards of the
included studies are summarised in Figure 3. No
publication bias exists in the studies (P>0.05)
(Appendix 1).
Descriptive statistics of CRB-65 risk strata
Of the 397 875 patients included in the studies,
66 827 (17%) were classified as low risk (score = 0),
283 902 (71%) intermediate risk (score = 1 or 2), and
47 146 (12%) high risk (score = 3 or 4) (Table 2).
However, the percentage of patients in the three risk
strata varied substantially depending on the setting of
care, with community-based individuals being
categorised into lower-risk categories. Observed
events were much less frequent in community-based
settings (Table 2).
Validation of CRB-65 risk strata
For lower-risk individuals, there are no events in
community-based patients with consequent over-
prediction; in low-risk hospital-based patients there is
relative under-prediction, but the 95% CI around this
estimate is compatible with accurate prediction
(Figure 4). In intermediate-risk groups, over-prediction
persists in community-based subjects, and observed
30-day mortality more closely matches predicted
mortality for hospital-based patients, with a tighter CI
(RR 0.91, 95% 95% CI 0.71 to 1.17) (Figure 5). For
high-risk patients, the magnitude of over-prediction
attenuates in community-based subjects, while
observed mortality matches that predicted by CRB-
65 in hospital-based patients (RR 1.01, 95% CI = 0.87
to 1.16) (Figure 6).
Sensitivity analysis
The study by Ewig et al has a significantly larger
number of included participants than all others, and
the results of that study dominate the meta-analysis
of the hospital-based patients.22 Sensitivity analysis
performed excluding this study shows similar results
but with broader CIs, with a low-risk-group RR of 1.25
indicating over-prediction of CRB-65 but with a wider
CI (0.60 to 2.59). The intermediate-risk group and
high-risk group RR estimates remain similar, being RR
0.98, (95% CI = 0.79 to 1.22) and RR 1.03 (95% CI =
0.87 to 1.21) respectively.
DISCUSSION
Summary of main findings
This systematic review shows that application of
CRB-65 accurately predicts 30-day mortality in
hospitalised patients across three strata of risk. In
British Journal of General Practice, October 2010
community settings, CRB-65 appears to over-predict
the probability of 30-day mortality across all strata of
predicted risk (Figures 4–6 ).
Strengths and limitations of the study
Pooling of data across 14 separate validation studies
enables assessment of the performance of CRB-65 in
different clinical settings, addressing validity,
generalisability, and precision of the estimates across
the three different strata of risk. Several limitations of
this study should be considered when interpreting the
results. The low event rate, particularly in community-
based studies, makes precise estimates about CRB-
65 performance less certain. Observed events (Table
2) are considerably lower than estimated in the
original derivation study (Figure 1) on which clinical
e428
Systematic Review
Hospital based Community based Total
Risk category n % Observed events, % n % Observed events, % n %
Low 65 802 16.6 2.4 1025 54.4 0.0 66 827 16.8
Intermediate 283 137 71.5 13.3 765 43.6 1.6 283 902 71.4
High 47 119 11.9 34.3 27 1.9 18.5 47 146 11.8
Table 2. Descriptive statistics for CRB-65 risk categories and observed risk for hospital and community-
based subjects.
Excluded studies
• Did not use predicition rule (n = 119)
Potentially relevant studies identified 
and screened for retrieval (n = 155)
Studies retrieved for more detailed
evaluation (n = 36)
Potentially appropriate studies to be 
included in meta-analysis (n = 15)
Studies included in meta-analysis
(n = 14)
Excluded studies
• Did not use CRB-65 rule (n = 21)
Excluded studies
• Only evaluated  patients with MRSA pneumonia
(n = 1)
Figure 2. Selection of
studies for inclusion in the
meta-analysis.
Yes
No
Unclear
Were the patients chosen in an unbiased fashion?
Do the patients represent a wide spectrum of disease?
Was there a blinded assessment of the rule criteria for
all patients?
Was there an explicit and accurate interpretation of
the predictor variables and the actual rule without
knowledge of the outcome?
Was there 100% follow-up?
0 5 10
Figure 3. Summary diagram
of the quality assessment
of the included studies.
MRSA = methicillin-resistant Staphylococcus aureus.
guidelines are based.3,4 Individual patient data could
not be obtained, so it was only possible to estimate
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predicted risk by applying the original risk estimates
to the strata in each of the validation studies, an
Community-based patients
Heterogeneity:τ2 = 0.00;χ2 = 0.09, df = 2 (P = 0.96); I2 = 0%
Test for overall effect:Z = 2.61 (P = 0.0009)
Events EventsTotal Total
Risk ratio
M-H, random, 95% CI
Risk ratio
M-H, random, 95% CI
Predicted Observed
Total events 13 0
Bauer 2006 3 215 0 215 7.00 (0.36 to 134.71)
Kruger 2008 4 295 0 295 9.00 (0.49 to 166.42)
Capelastegul 2006 6 515 0 515 13.00 (0.73 to 230.17)
Subtotal (95% CI) 1025 1025 9.41 (1.75 to 50.66)
Hospital-based patients
Heterogeneity:τ2 = 0.12;χ2 = 10.68, df = 9 (P = 0.30); I2 = 16%
Test for overall effect:Z = 1.35 (P = 0.18)
Total events 787 1555
Chalmers 2007 3 217 4 217 0.75 (0.17 to 3.31)
Kruger 2008 3 262 2 262 1.50 (0.25 to 8.90)
Barlow 2007 1 71 0 71 3.00 (0.12 to 72.42)
Subtotal (95% CI) 65802 65802 0.70 (0.42 to 1.18)
Myint 2006 0 3 0 3 Not estimable
Zuberi 2008 0 34 0 34 Not estimable
Schaaf 2007 0 32 0 32 Not estimable
Buising 2007 1 100 0 100 3.00 (0.12 to 72.77)
Capelastegul 2006 2 201 0 201 5.00 (0.24 to 103.50)
Bauer 2006 4 299 0 299 9.00 (0.49 to 166.43)
Ewig 2009 770 64267 1541 64267 0.50 (0.46 to 0.54)
Man 2007 2 128 3 128 0.67 (0.11 to 3.92)
Schuetz 2008 1 109 109 0.25 (0.03 to 2.20)4
Menendez 2009 10 79 79 0.33 (0.01 to 8.06)
0.01 0 . 1 1 10 100
Underprediction Overprediction
Figure 4. Low-risk group
(score = 0) predicted and
observed deaths in
community and hospital
settings.
Community-based patients
Heterogeneity:τ2 = 0.00;χ2 = 2.03, df = 3 (P = 0.57); I2 = 0%
Test for overall effect:Z = 5.01 (P = 0.00001)
Events EventsTotal Total
Risk ratio
M-H, random, 95% CI
Risk ratio
M-H, random, 95% CI
Predicted Observed
Total events 63 12
Bont 2008 24 291 7 291 3.43 (1.50 to 7.83)
Bauer 2006 11 133 2 133 5.50 (1.24 to 24.34)
Kruger 2008 15 180 2 180 7.50 (1.74 to 32.32)
Subtotal (95% CI) 765 765 4.84 (2.61 to 8.96)
Hospital-based patients
Heterogeneity:τ2 = 0.15;χ2 = 78.91, df = 12 (P = 0.00001); I2 = 85%
Test for overall effect:Z = 0.71 (P = 0.48)
Total events 23020 37745
Chalmers 2007 51 629 47 629 1.09 (0.74 to 1.59)
Man 2007 64 783 58 783 1.10 (0.78 to 1.55)
Kruger 2008 57 703 47 703 1.21 (0.84 to 1.76)
Subtotal (95% CI) 283137 283137 0.91 (0.71 to 1.17)
Barlow 2007 23 281 49 281 0.47 (0.29 to 0.75)
Schuetz 2008 23 259 35 259 0.60 (0.36 to 1.00)
Ewig 2009 22592 277890 37310 277890 0.61 (0.60 to 0.62)
Bauer 2006 60 735 46 735 1.30 (0.90 to 1.89)
Menendez 2009 26 319 18 319 1.44 (0.81 to 2.58)
Buising 2007 35 433 21 433 1.67 (0.99 to 2.82)
Capelastegul 2006 87 819 82 819 0.82 (0.60 to 1.11)
Schaaf 2007 5 58 5 58 1.00 (0.31 to 3.27)
Zuberi 2008 8 94 94 0.62 (0.27 to 1.42)13
Myint 2006 1411 134 134 0.79 (0.37 to 1.67)
0.05 0.2 1 5 20
Underprediction Overprediction
Capelastegul 2006 13 161 1 161 13.00 (1.72 to 98.21)
Figure 5. Intermediate-
risk group (score = 1 or 2)
predicted and observed
deaths in community and
hospital settings.
M-H = Mantel-Haenszel statistical method.
M-H = Mantel-Haenszel statistical method.
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approach adopted in a community-based validation
study.8 However, as CRB-65 relies on unequivocal
clinical characteristics, it is unlikely that
misclassification of patients occurred. The hospital-
based patients category is dominated by one large
study that contributed 98% of the total patient
dataset;22 however, sensitivity analysis indicates that
results are similar when this study is excluded from
the meta-analysis. One study only measured patients
who suffered from pneumococcal pneumonia,19 but
rather than exclude this study, it was included albeit
that the event rate is low and is likely to produce an
under-prediction of risk. While more studies validating
CRB-65 in primary care are needed, it is likely that a
large number of patients will need to be recruited to
enable precise estimates of performance to be
made.9 The outcome of interest — 30-day mortality —
is the final clinical endpoint but more frequently
occurring intermediate outcomes might be more
relevant to clinical care in a primary care setting, such
as admission to hospital, clinical deterioration, or re-
consultation. Alternatively, quality of life scores or
duration of illness may be more indicative of
morbidity associated with CAP, and are more likely to
be outcomes of more immediate relevance to
patients. Lastly, some studies assessed hospital
mortality rather than 30-day mortality and this could
account for differences in the performance of the rule
between different studies.
Comparison with existing literature
CRB-65 is one of several clinical prediction rules that
assess the severity of CAP. Other clinical prediction
rules that address complications of CAP include the
Pneumonia Severity Index (PSI) and CURB-65. The PSI
was the first clinical prediction rule derived and
validated as a prognostic indicator for CAP; however,
its use of 20 different clinical variables makes
calculation complex.24 In addition, the inclusion of
laboratory values limits its use in primary care settings,
since many GPs will not have immediate access to
such investigations. CURB-65 includes the
measurement of urea, and this also limits is timeliness
and value in primary care.25 The PSI has been
compared to the CURB-65 rule in a number of
studies,17,29,26–29 and the CPRs have been found to
perform similarly.25 These preliminary results indicate
that the greater number of variables in the PSI does not
significantly strengthen the power of the rule, and
therefore their inclusion may only stand as a hindrance
to its use.
A number of other clinical prediction rules have been
derived with promising initial results, including SCAP,28
SOAR,23 and CORB,13 along with one clinical prediction
rule derived entirely in primary care.30,31 The hospital-
derived CPRs all contain some or all of confusion,
tachypnoea, hypotension, and age in their scoring, and
therefore have similarities to CRB-65; however, these
rules differ by including other criteria (such as
Community-based patients
Heterogeneity:τ2 = 0.00;χ2 = 1, df = 1 (P = 0.66); I2 = 0%
Test for overall effect:Z = 0.91 (P = 0.36)
Events EventsTotal Total
Risk ratio
M-H, random, 95% CI
Risk ratio
M-H, random, 95% CI
Predicted Observed
Total events 8 5
Kruger 2008 0 1 0 1 No estimable
Bauer 2006 1 3 1 3 1.00 (0.10 to 9.61)
Bont 2008 7 23 4 23 1.75 (0.59 to 5.17)
Subtotal (95% CI) 27 27 1.58 (0.59 to 4.19)
Hospital-based patients
Heterogeneity:τ2 = 0.02;χ2 = 18.96, df = 12 (P = 0.09); I2 = 37%
Test for overall effect:Z = 0.07 (P = 0.95)
Total events 14726 16158
Chalmers 2007 50 161 46 161 1.09 (0.78 to 1.52)
Man 2007 33 105 26 105 1.27 (0.82 to 1.96)
Buising 2007 65 207 51 207 1.27 (0.93 to 1.74)
Subtotal (95% CI) 47119 47119 1.01 (0.87 to 1.16)
Zuberi 2008 3 9 5 9 0.60 (0.20 to 1.79)
Capelastegul 2006 25 80 36 80 0.69 (0.46 to 1.04)
Barlow 2007 21 67 30 67 0.70 (0.45 to 1.09)
Myint 2006 17 55 13 55 1.31 (0.70, to 2.43)
Bauer 2006 16 50 11 50 1.45 (0.75 to 2.81)
Kruger 2008 21 67 12 67 1.75 (0.94 to 3.26)
Ewig 2009 14453 46249 15903 46249 0.91 (0.89 to 0.93)
Schuetz 2008 2 5 2 5 1.00 (0.22 to 4.56)
Schaaf 2007 5 15 15 0.83 (0.32, to 2.15)6
Menendez 2009 1415 134 134 0.88 (0.50 to 1.56)
0.02 0.1 1 10 50
Underprediction Overprediction
Figure 6. High-risk group
(score = 3 or 4) predicted
and observed deaths in
community and hospital
settings.
M-H = Mantel-Haenszel statistical method.
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oxygenation) and by the outcomes they predict:
development of severe CAP,28 requirement of
ventilatory or inotropic support,13 or death.13,23 The
primary care-derived clinical prediction rule has
different criteria to CRB-65 (diagnosis, age, comorbid
conditions, medications, and recent hospitalisation),
and the additional outcome measure of hospitalisation
along with death. Although preliminary results are
promising, these clinical prediction rules have yet to be
validated to a great extent, and therefore their use in
clinical practice is more uncertain.9 The use of generic
sepsis and early-warning scores has also been
proposed but preliminary results indicate that they are
less effective than pneumonia-specific rules.11
In terms of comparative prognostic value when
comparing CURB-65 with CRB-65, it appears that
additional urea measurement does not substantially
improve the predictive value of CURB-65.12–15,17,20,23 This,
along with the simplicity of CRB-65, indicates that it is
emerging as potentially the most useful severity score
for CAP.
Implications for future research and clinical
practice
The inclusion and exclusion criteria for this meta-
analysis were broad and reflect those used in the
validation studies themselves but also do prove to be
a limitation in the analysis. Significant common
comorbid illnesses are known to have an impact on
severity;2,31–34 their impact was not assessed in the
validation studies. Other known predictors of severity
such as nursing home residency, recent
hospitalisations, and recent antibiotics were also not
addressed.2,31,32,34 However, the derivation cohort for
CRB-65 specifically included patients with these
predictors, and the clinical prediction rule was
developed adjusting for these prognostic markers. If
included separately in a severity assessment alongside
CRB-65, these factors may improve prediction;
however, their presence in both the derivation and
validation cohorts indicates that the components of
CRB-65 have independent predictive characteristics.
Another additional way in which prediction may be
improved is with the use of near-patient tests such as
C-reactive protein or procalcitonin. These tests have
been shown to be an adjunct in the diagnosis of CAP,
and preliminary results indicate they may also have
predictive value for severity.16,18,35,36 A role for these tests
may be found as an additional predictor of severity
alongside CRB-65, but it is more likely they could be
used as a further discriminator for the appropriate site
of care after application of CRB-65.
In the context of clinical management strategies,
over half of patients in community settings were
classified as low risk, with over 40% classified as
intermediate risk (Table 2). Within this group, CRB-65
was found to over-predict the risk of death. However,
the event rate level is low and the extent of over-
prediction by CRB-65 remains uncertain. It is possible
that investigation of other clinical predictors or near-
patient tests may improve prediction, but this requires
further study. The addition of other risk factors such as
comorbidity would also enable different thresholds to
be set in community settings, reflecting the lower
absolute number of events compared with hospital-
based settings (Table 2).
In hospital-based patients, the severity scores were
more evenly distributed, with two-thirds in the
intermediate-risk group and one-fifth in the high-risk
group. As a prognostic tool, CRB-65 appears to be
more clinically useful in hospital settings. As clinical
medicine is being driven by evidence-based standards
of care,37 prognostic rules are likely to become the
benchmark against which acceptable standards of
care are judged. In this context, as this systematic
review shows, it is important that caution is used when
extrapolating evidence from studies that have recruited
from hospital-based rather than community-based
settings. Accurate risk stratification of likely prognosis
requires confirmatory validation in similar populations
of patients and settings of care.7
Finally, future work with the CRB-65 rule will allow for
more robust determination of its usefulness in both
hospital and community-based practice. Assessment
of the impact of the rule on antibiotic prescribing,
especially in the context of a low-risk patient, will be
worthwhile. Also, determining an appropriate threshold
for referral from primary care to hospital may be
established, since the community-based results
indicate that the rule may over-predict mortality in this
setting, particularly in the low- and intermediate-risk
groups (Figures 4 and 5).
In conclusion, CRB-65 has been found to accurately
predict severity of pneumonia and resultant deaths in a
hospital setting across all strata of risk. CRB-65 has
not been validated sufficiently in primary care settings
and preliminary findings suggest over-prediction, so its
value as a prognostic indicator in the community
remains uncertain.
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Egger’s test for small-study effects: regress standard normal deviate of intervention effect estimate
against its standard error
• Number of studies = 15
• Root MSE = 2.029
Std_Eff | Coefficient Standard error t P>|t| 95% CI
slope | 0.259 0.271 0.950 0.357 –0.327 to 0.844
bias | –1.549 1.277 –1.210 0.247 –4.309 to 1.211
Begg’s test for small-study effects: rank correlation between standardised intervention effect and its
standard error
• adjusted Kendall’s Score (P — Q) = –17
• Standard deviation of score = 20.21
• Number of studies = 15
• z = 0.79 (continuity corrected)
• Pr > |z| = 0.428 (continuity corrected)
Peter’s test for small-study effects: regress intervention effect estimate on 1/Ntot, with weights S × F/Ntot
• Number of studies = 15
• Root MSE = 0.937
Std_Eff | Coefficient Standard error t P>|t| 95% CI
bias | 78.904 349.655 0.230 0.825 –676.479 to 834.287
constant | –0.440 0.359 –1.230 0.242 –1.215 to 0.336
Harbord’s modified test for small-study effects: regress Z/√(V) on √(V) where Z is efficient score and V is
score variance
• Number of studies = 15
• Root MSE = 2.225
Z/√(V) Coefficient Standard error t P>|t| 95% CI
√(V) 0.293 0.331 0.890 0.392 –0.422 to 1.008
bias | –1.871 1.595 –1.170 0.262 –5.317 to 1.576
MSE = mean squared error.
Appendix 1. Statistical tests for lack of ‘small-study effects’ or publication bias
(funnel plot results).
Appendix 1. Funnel plot
with 95% confidence limits
for existence of
publication bias in the
meta-analysis.
